Neurocrine Biosciences to Acquire Celeno Therapeutics

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

April 6, 2026

Healthcare Services

Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Pharmaceuticals

AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.

Global Cord Blood Corporation Acquires Cellenkos, Inc.

April 29, 2022

Biotechnology

Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

PTC Therapeutics to Acquire Censa Pharmaceuticals

May 6, 2020

Biotechnology

PTC Therapeutics has entered into an agreement to acquire Censa Pharmaceuticals to obtain CNSA-001 (sepiapterin), a Phase 3–ready oral therapy for phenylketonuria (PKU) and other BH4-pathway disorders. Under the deal PTC will pay approximately $10 million cash upfront and up to 850,000 shares of PTC common stock, plus potential development, regulatory and sales milestones totaling hundreds of millions of dollars.